EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89.16 USD | -1.06% |
|
+2.81% | +16.92% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 6.56B | Sales 2025 * | 7.2B | Capitalization | 53.72B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.62B | Net income 2025 * | 1.86B | EV / Sales 2024 * | 7.93 x |
| Net cash position 2024 * | 1.7B | Net cash position 2025 * | 2.89B | EV / Sales 2025 * | 7.06 x |
| P/E ratio 2024 * |
33.5
x | P/E ratio 2025 * |
29
x | Employees | 19,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 day | -1.06% | ||
| 1 week | +2.81% | ||
| Current month | +5.30% | ||
| 1 month | +3.13% | ||
| 3 months | +3.55% | ||
| 6 months | +33.27% | ||
| Current year | +16.92% |
1 week
84.67
90.98
1 month
83.5090.98
Current year
71.6796.12
1 year
60.5796.12
3 years
60.57131.73
5 years
51.51131.73
10 years
13.02131.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Chairman | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 42 M€ | +2.30% | - | |
| 2.34% | 17 M€ | +7.73% | - | |
| 2.13% | 6 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 89.14 | -1.08% | 2,070,779 |
| 24-05-16 | 90.11 | -0.06% | 2,204,301 |
| 24-05-15 | 90.16 | +4.28% | 3,111,296 |
| 24-05-14 | 86.46 | +2.08% | 2,127,401 |
| 24-05-13 | 84.7 | -2.33% | 2,579,306 |
Delayed Quote Nyse, May 17, 2024 at 04:00 pm EDT
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
89.14
USD
Average target price
95.9
USD
Spread / Average Target
+7.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.92% | 53.72B | |
| +12.15% | 227B | |
| +14.90% | 197B | |
| +18.22% | 141B | |
| +29.15% | 110B | |
| +0.53% | 64.15B | |
| +6.33% | 51.75B | |
| +10.93% | 45.2B | |
| +5.87% | 37.37B | |
| +27.06% | 32.11B |
- Stock Market
- Equities
- EW Stock
